gemcitabine has been researched along with gambogic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, X; Meng, Q; Song, Z; Wang, H; Xia, G | 1 |
| Chauhan, SC; Hatami, E; Jaggi, M; Nagesh, PKB; Yallapu, MM | 1 |
2 other study(ies) available for gemcitabine and gambogic acid
| Article | Year |
|---|---|
Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).
Topics: Animals; Apoptosis; Caspase 3; Caspase 9; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mice; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Xanthones; Xenograft Model Antitumor Assays | 2017 |
Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer.
Topics: A549 Cells; Adult; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Male; Mice, Nude; Middle Aged; Pilot Projects; Tumor Cells, Cultured; Xanthones; Xenograft Model Antitumor Assays | 2020 |